Sanofi-Aventis to cut up to 10% of US sales force
This article was originally published in Scrip
Executive Summary
Sanofi-Aventisis to make single-digit percentage cuts to its US sales force, the company has confirmed to Scrip. The France-based pharma giant currently has around 6,500 reps in the US, meaning that up to 650 employees could be cut. Sanofi-Aventis's new CEO Chris Viebacher took up his position at the beginning of this month but the company said that the cuts were part of a process that had been decided months before he joined. The company reduced its sales force by 817 and the number of staff at its headquarters in France by 110 in October (ScripOnline, October 3rd, 2008).
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.